• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Pregnancy and Postpartum Course
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Authors » Joshua Feder, MD
Joshua Feder, MD

Joshua Feder, MD

Dr. Joshua Feder studied mathematics and medicine at Boston University, Psychiatry at Naval Regional Medical Center San Diego, serving the first Gulf War in child and adolescent psychiatry fellowship at Tripler Army Medical Center in Honolulu, and eventually became Chief of Child Psychiatry at the National Naval Medical Center in Bethesda, MD. Dr. Feder now practices in Solana Beach, California, and serves as Executive Medical Director at Positive Development, providing relationship-based support for families, with research at UCSD, SDSU, Fielding Graduate University, An Najah National University, Quicksilver Software, Autism Is inclusion program, and Programmatic Lead for the International Networking Group on Peace Building with Young Children, with projects in the US, Northern Ireland, and the Middle East. Dr. Feder co-authored the first American Academy of Child & Adolescent Psychiatry Practice Parameter on Autism and serves as Co-Chair of the Disaster & Trauma Committee at AACAP. Dr Feder was founding policy chair for the California Association for Infant Mental Health and advocates worldwide on access to care, climate policy, and peacebuilding. His recent books include Child Medication Fact Book for Psychiatric Practice, Second Edition (2023) and Prescribing Psychotropics (2021).

Articles
Products

ARTICLES

Algorithm

Bipolar Disorder Treatment Algorithm for Children and Adolescents

September 1, 2023
Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Bipolar disorder treatment algorithm for children and adolescents


Read More
Fact Sheet

Ramelteon (Rozerem) for Children and Adolescents

September 1, 2023
Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Ramelteon is a melatonin receptor agonist with no data in pediatric patients. 




Read More
Fact Sheet

Propranolol (Inderal) for Children and Adolescents

September 1, 2023
Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

May be effective and safe for use in performance anxiety, particularly when the sedating or cognitive side effects of benzos could interfere with an individual’s performance, but there are no data in kids.




Read More
Fact Sheet

Prazosin (Minipress) for Children and Adolescents

September 1, 2023
Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Although there are only minimal data, consider prazosin for PTSD in kids, especially for PTSD-associated sleep disturbances and nightmares, but monitor BP.




Read More
Fact Sheet

Lorazepam (Ativan) for Children and Adolescents

September 1, 2023
Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Benzodiazepines are generally only appropriate for use before procedures. Lorazepam probably has less risk of misuse than others. Lorazepam is also the first-line, but off-label, treatment for catatonia.




Read More
Fact Sheet

Clonazepam (Klonopin) for Children and Adolescents

September 1, 2023
Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Due to the lack of large randomized controlled data to support its use and the potential for side effects, clonazepam should be avoided. If you decide to use it, keep it very short term and deploy it adjunctively in kids who exhibit only partial response to first-line therapies (SSRI, SNRI) or have severe anxiety.




Read More
Fact Sheet

Buspirone (BuSpar) for Children and Adolescents

September 1, 2023
Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Despite the lack of large randomized controlled data to support first-line use, buspirone may be used adjunctively in kids who exhibit partial response to first-line therapies for anxiety (SSRI, SNRI), without the sedation and abuse potential burden of benzodiazepines.




Read More
Fact Sheet

Antihistamines (Diphenhydramine, Doxylamine, Hydroxyzine) for Children and Adolescents

September 1, 2023
Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Antihistamines can be effective sleepers for some kids and are the most prescribed by pediatricians, although some patients may experience too much grogginess (“hangover”) in the morning or a paradoxical excitation.




Read More
Algorithm

Anxiety Treatment Algorithm for Children and Adolescents

September 1, 2023
Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Anxiety treatment algorithm for children and adolescents


Read More
Fact Sheet

Anxiolytics and Hypnotics General Tips on Child and Adolescent Psychopharmacology

September 1, 2023
Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Anxiety is perhaps the most frequent symptom for which child psychiatrists are consulted.



Read More
View All Articles by Joshua Feder, MD
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB8e_SpiralCover.png

    Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

    Updated 2026 prescriber's guide.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2714175187.jpg
    General Psychiatry

    Wounded Healers: Freud and Jung

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.